Effect of interferon-β and atorvastatin on Th1/Th2 cytokines in multiple sclerosis

Neurochemistry International

Volumn 53, Issue 1-2, 2008, Pages 17-21

  Sellner, Johann ^a,b   Greeve, Isabell ^a   Findling, Oliver ^a   Kamm, Christian P ^a   Minten, Carsten ^c   Engelhardt, Britta ^c   Grandgirard, Denis ^d   Leib, Stephen L ^d   Mattle, Heinrich P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Atorvastatin; Biomarker; Cytokine; Interferon ; Multiple sclerosis; Multiplex protein assay

Indexed keywords

ATORVASTATIN; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ASSAY; HUMAN; IMMUNOMODULATION; MONOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE;

ADOLESCENT; ADULT; CYTOKINES; DATA INTERPRETATION, STATISTICAL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON TYPE I, RECOMBINANT; INTERLEUKIN-5; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PYRROLES; TH1 CELLS; TH2 CELLS;

EID: 45849137448     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2008.04.004     Document Type: Article

References (40)

1. Achiron A., and Gurevich M. Peripheral blood gene expression signature mirrors central nervous system disease: the model of multiple sclerosis. Autoimmun. Rev. 5 (2006) 517-522
2. Birnbaum G., Altafullah I., and Reder A. A double blind, placebo controlled trial of atorvastatin in combination with subcutaneous interferon beta 1a in persons with multiple sclerosis. Neurology 68 (2007) A206-A207
3. Dunn S.E., Youssef S., Goldstein M.J., Prod'homme T., Weber M.S., Zamvil S.S., and Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 203 (2006) 401-412
4. Elenkov I.J. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem. Int. 52 (2008) 40-51
5. Graber J.J., Ford D., Zhan M., Francis G., Panitch H., and Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J. Neuroimmunol. 185 (2007) 168-174
6. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., and Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11 (2005) 328-334
7. Gutcher I., and Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J. Clin. Invest. 117 (2007) 1119-1127
8. Hamamcioglu K., and Reder A.T. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult. Scler. 13 (2007) 459-470
9. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., and Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6 (2005) 1123-1132
10. Hemmer B., Nessler S., Zhou D., Kieseier B., and Hartung H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2 (2006) 201-211
11. Hollifield R.D., Harbige L.S., Pham-Dinh D., and Sharief M.K. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 36 (2003) 133-141
12. Kantor A.B., Deng J., Waubant E., Lin H., Becker C.H., Lacy J.R., Perrone A.M., Bennett D., and Goelz S.E. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad-based phenotypic profiling. J. Neuroimmunol. 188 (2007) 103-116
13. Kreymborg K., Etzensperger R., Dumoutier L., Haak S., Rebollo A., Buch T., Heppner F.L., Renauld J.C., and Becher B. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J. Immunol. 179 (2007) 8098-8104
14. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
15. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
16. Liu J., Marino M.W., Wong G., Grail D., Dunn A., Bettadapura J., Slavin A.J., Old L., and Bernard C.C. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4 (1998) 78-83
17. Makhlouf K., Weiner H.L., and Khoury S.J. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J. Neuroimmunol. 119 (2001) 145-149
18. Miller A., Glass-Marmor L., Abraham M., Grossman I., Shapiro S., and Galboiz Y. Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin. Neurol. Neurosurg. 106 (2004) 249-254
19. Nakamura K., Masuda H., Kariyazono H., Arima J., Iguro Y., Yamada K., and Sakata R. Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting. Cytokine 36 (2006) 201-210
20. Nath N., Giri S., Prasad R., Singh A.K., and Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J. Immunol. 172 (2004) 1273-1286
21. Neuhaus O., and Hartung H.P. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev. Neurother. 7 (2007) 547-556
22. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., and Archelos J.J. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59 (2002) 990-997
23. Ochi H., Feng-Jun M., Osoegawa M., Minohara M., Murai H., Taniwaki T., and Kira J. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. J. Neurol. Sci. 222 (2004) 65-73
24. Ozenci V., Kouwenhoven M., and Link H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult. Scler. 8 (2002) 396-404
25. Pahan K., Sheikh F.G., Namboodiri A.M., and Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100 (1997) 2671-2679
26. Paintlia A.S., Paintlia M.K., Singh A.K., Stanislaus R., Gilg A.G., Barbosa E., and Singh I. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by lovastatin. J. Neurosci. Res. 77 (2004) 63-81
27. Pellegrini P., Totaro R., Contasta I., Berghella A.M., Russo T., Carolei A., and Adorno D. IFNbeta-1a treatment and reestablishment of Th1 regulation in MS patients: dose effects. Clin. Neuropharmacol. 27 (2004) 258-269
28. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., and Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58 (2005) 840-846
29. Rio J., and Montalban X. Interferon-beta 1b in the treatment of multiple sclerosis. Expert Opin. Pharmacother. 6 (2005) 2877-2886
30. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., and Tuohy V.K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50 (1998) 1294-1300
31. Salama H.H., Kolar O.J., Zang Y.C., and Zhang J. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult. Scler. 9 (2003) 28-31
32. Sellner J., Greeve I., Findling O., Grandgirard D., Leib S.L., and Mattle H.P. Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis. Clin. Exp. Immunol. 152 (2008) 280-284
33. Sellner J., Greeve I., Leib S.L., and Mattle H.P. Atorvastatin does not alter interferon beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis. Arch. Neurol. 65 (2008) 672-674
34. Sellner, J., Greeve, I., Mattle, H.P., in press-b. Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Mult. Scler. doi:10.1177/1352458508091368.
35. Sena A., Pedrosa R., and Morais M.G. Beneficial effect of statins in multiple sclerosis: is it dose-dependent?. Atherosclerosis 191 (2007) 462
36. Wandinger K.P., Sturzebecher C.S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., McFarland H.F., and Martin R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50 (2001) 349-357
37. Waubant E., Gee L., Bacchetti P., Sloan R., Cotleur A., Rudick R., and Goodkin D. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J. Neuroimmunol. 112 (2001) 139-145
38. Weber M.S., Steinman L., and Zamvil S.S. Statins-treatment option for central nervous system autoimmune disease?. Neurotherapeutics 4 (2007) 693-700
39. Wiesemann E., Sonmez D., Heidenreich F., and Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells. J. Neuroimmunol. 123 (2002) 160-169
40. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84